|
1
|
Gamliel Z: Incidence, epidemiology, and
etiology of esophageal cancer. Chest Surg Clin N Am. 10:441–450.
2000.PubMed/NCBI
|
|
2
|
Holmes RS and Vaughan TL: Epidemiology and
pathogenesis of esophageal cancer. Semin Radiat Oncol. 17:2–9.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wheeler JB and Reed CE: Epidemiology of
esophageal cancer. Surg Clin North Am. 92:1077–1087. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sugimura K, Miyata H, Tanaka K, Takahashi
T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M and Doki
Y: High infiltration of tumor-associated macrophages is associated
with a poor response to chemotherapy and poor prognosis of patients
undergoing neoadjuvant chemotherapy for esophageal cancer. J Surg
Oncol. 111:752–759. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cao B, Shi Q and Wang W: Higher expression
of SIRT1 induced resistance of esophageal squamous cell carcinoma
cells to cisplatin. J Thorac Dis. 7:711–719. 2015.PubMed/NCBI
|
|
6
|
Liu L, Zuo LF, Zuo J and Wang J:
Artesunate induces apoptosis and inhibits growth of Eca109 and
Ec9706 human esophageal cancer cell lines in vitro and in
vivo. Mol Med Rep. 12:1465–1472. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang GZ, Wang ZJ, Bai F, Qin XJ, Cao J, Lv
JY and Zhang MS: Epigallocatechin-3-gallate protects HUVECs from
PM2.5-induced oxidative stress injury by activating critical
antioxidant pathways. Molecules. 20:6626–6639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao H, Xie P, Li X, Zhu W, Sun X, Sun X,
Chen X, Xing L and Yu J: A prospective phase II trial of EGCG in
treatment of acute radiation-induced esophagitis for stage III lung
cancer. Radiother Oncol. 114:351–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Xu J, Li J, Du L, Chen T, Liu P,
Peng S, Wang M and Song H: Epigallocatechin-3-gallate attenuates
lipopolysaccharide-induced mastitis in rats via suppressing MAPK
mediated inflammatory responses and oxidative stress. Int
Immunopharmacol. 26:147–152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shankar S, Ganapathy S and Srivastava RK:
Green tea polyphenols: Biology and therapeutic implications in
cancer. Front Biosci. 12:4881–4899. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thangapazham RL, Singh AK, Sharma A,
Warren J, Gaddipati JP and Maheshwari RK: Green tea polyphenols and
its constituent epigallocatechin gallate inhibits proliferation of
human breast cancer cells in vitro and in vivo. Cancer Lett.
245:232–241. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shin YS, Kang SU, Park JK, Kim YE, Kim YS,
Baek SJ, Lee SH and Kim CH: Anti-cancer effect of
(−)-epigallocatechin-3-gallate (EGCG) in head and neck cancer
through repression of transactivation and enhanced degradation of
β-catenin. Phytomedicine. 23:1344–1355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qiao Y, Cao J, Xie L and Shi X: Cell
growth inhibition and gene expression regulation by
(−)-epigallocatechin-3-gallate in human cervical cancer cells. Arch
Pharm Res. 32:1309–1315. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Min NY, Kim JH, Choi JH, Liang W, Ko YJ,
Rhee S, Bang H, Ham SW, Park AJ and Lee KH: Selective death of
cancer cells by preferential induction of reactive oxygen species
in response to (−)-epigallocatechin-3-gallate. Biochem Biophys Res
Commun. 421:91–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siddiqui WA, Ahad A and Ahsan H: The
mystery of BCL2 family: Bcl-2 proteins and apoptosis: An update.
Arch Toxicol. 89:289–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aouacheria A, Cibiel A, Guillemin Y,
Gillet G and Lalle P: Modulating mitochondria-mediated apoptotic
cell death through targeting of Bcl-2 family proteins. Recent Pat
DNA Gene Seq. 1:43–61. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi LS, Wang H, Wang F, Feng M, Wang M and
Guan WX: Effects of gastrokine-2 expression on gastric cancer cell
apoptosis by activation of extrinsic apoptotic pathways. Mol Med
Rep. 10:2898–2904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi J, Liu F, Zhang W, Liu X, Lin B and
Tang X: Epigallocatechin-3-gallate inhibits nicotine-induced
migration and invasion by the suppression of angiogenesis and
epithelial-mesenchymal transition in non-small cell lung cancer
cells. Oncol Rep. 33:2972–2980. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Irimie AI, Braicu C, Zanoaga O, Pileczki
V, Gherman C, Berindan-Neagoe I and Campian RS:
Epigallocatechin-3-gallate suppresses cell proliferation and
promotes apoptosis and autophagy in oral cancer SSC-4 cells. Onco
Targets Ther. 8:461–470. 2015.PubMed/NCBI
|
|
20
|
Tang G, Zhang Z, Qian H, Chen J, Wang Y,
Chen X, Chen B and Chen Y: (−)-Epigallocatechin-3-gallate inhibits
osteosarcoma cell invasiveness by inhibiting the MEK/ERK signaling
pathway in human osteosarcoma cells. J Environ Pathol Toxicol
Oncol. 34:85–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bao H and Peng A: The green tea
polyphenol(−)-epigallocatechin-3-gallate and its beneficial roles
in chronic kidney disease. J Transl Int Med. 4:99–103. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khan MA, Hussain A, Sundaram MK, Alalami
U, Gunasekera D, Ramesh L, Hamza A and Quraishi U:
(−)-Epigallocatechin-3-gallate reverses the expression of various
tumor-suppressor genes by inhibiting DNA methyltransferases and
histone deacetylases in human cervical cancer cells. Oncol Rep.
33:1976–1984. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Xie Y, Feng Y, Zhang L, Huang X,
Shen X and Luo X: (−)-Epigallocatechingallate induces apoptosis in
B lymphoma cells via caspase-dependent pathway and Bcl-2 family
protein modulation. Int J Oncol. 46:1507–1515. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li YJ, Wu SL, Lu SM, Chen F, Guo Y, Gan
SM, Shi YL, Liu S and Li SL: (−)-Epigallocatechin-3-gallate
inhibits nasopharyngeal cancer stem cell self-renewal and migration
and reverses the epithelial-mesenchymal transition via NF-κB p65
inactivation. Tumour Biol. 36:2747–2761. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang C, Du W and Yang D: Inhibition of
green tea polyphenol EGCG ((−)-epigallocatechin-3-gallate) on the
proliferation of gastric cancer cells by suppressing canonical
wnt/β-catenin signalling pathway. Int J Food Sci Nutr. 67:818–827.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shin YS, Kang SU, Park JK, Kim YE, Kim YS,
Baek SJ, Lee SH and Kim CH: Anti-cancer effect of
(−)-epigallocatechin-3-gallate (EGCG) in head and neck cancer
through repression of transactivation and enhanced degradation of
β-catenin. Phytomedicine. 23:1344–1355. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li M, Li JJ, Gu QH, An J, Cao LM, Yang HP
and Hu CP: EGCG induces lung cancer A549 cell apoptosis by
regulating Ku70 acetylation. Oncol Rep. 35:2339–2347. 2016.
View Article : Google Scholar : PubMed/NCBI
|
